Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Brian A. Boone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9006-059X; OpenAlex author ID A5015514912; NIH RePORTER profile ID 11203517. Sources: OpenAlex.

Their work

Papers
43 (first author 1, last author 18)
Trials
0
Grants
3
Labs led
1
Collaborators
107
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: 3 papers · 2019: 6 papers · 2020: 5 papers · 2021: 6 papers · 2022: 3 papers · 2023: 2 papers, 1 grant · 2024: 4 papers · 2025: 5 papers · 2026: 4 papers, 2 grants

Papers 43

  1. Exploratory single-nucleus multiomics analysis of myeloid cell states associated with neoadjuvant chemotherapy response in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.70810↗
  2. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Co-author DOI 10.1002/jso.70179↗
  3. Application of group A streptococcal collagen-like protein 1-expressing Lactococcus as a novel immunotherapeutic against pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-026-36657-1↗
  4. Caught in the NET: A Review on the Emerging Role of Neutrophil Extracellular Traps in PDAC Development. Last author DOI 10.1177/15330338261470694↗
  5. Neutrophil extracellular trap inhibition revitalizes PDAC immunotherapy responsiveness via reduced fibrosis and TCF1+CD8+ progenitor T-cell expansion. Last author DOI 10.1080/2162402x.2025.2601394↗
  6. Neutrophil Extracellular Traps Modulate Recruitment and Immunosuppression of Macrophages in Pancreatic Adenocarcinoma. Last author DOI 10.1158/2326-6066.cir-24-0534↗
  7. Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition. Last author DOI 10.1186/s12950-025-00456-8↗
  8. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
  9. Imaging Reactive Oxygen Species with L-012 Reveals Neutrophil Extracellular Trap Formation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/antiox14121473↗
  10. Analysis of single nuclear chromatin accessibility reveals unique myeloid populations in human pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.1595↗
  11. Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer. Co-author DOI 10.1007/s00262-024-03647-z↗
  12. Group A streptococcal collagen-like protein 1 restricts tumor growth in murine pancreatic adenocarcinoma and inhibits cancer-promoting neutrophil extracellular… Last author DOI 10.3389/fimmu.2024.1363962↗
  13. Unraveling the gut microbiome's contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives. Last author DOI 10.3389/fimmu.2024.1434771↗
  14. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  15. Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer. Last author DOI 10.3389/fonc.2023.1217095↗
  16. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  17. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  18. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach? Last author DOI 10.1097/mpa.0000000000002147↗
  19. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/cji.0000000000000370↗
  20. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Last author DOI 10.1111/cts.13029↗
  21. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  22. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Last author DOI 10.3390/biom11060901↗
  23. Macrophage and Neutrophil Interactions in the Pancreatic Tumor Microenvironment Drive the Pathogenesis of Pancreatic Cancer. Co-author DOI 10.3390/cancers14010194↗
  24. Robot Assisted Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer: Surgical Planning and Technique. Last author DOI 10.3791/62232↗
  25. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  26. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-019-08094-0↗
  27. ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-019-08136-7↗
  28. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Last author DOI 10.21203/rs.3.rs-125334/v1↗
  29. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.21152↗
  30. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Co-author DOI 10.1007/s00277-019-03692-0↗
  31. Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? Last author DOI 10.1016/j.hpb.2018.10.012↗
  32. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  33. Pancreatic Cancer Presenting as a Pancreatic Duct Disruption. Last author DOI 10.1155/2019/6381249↗
  34. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. Co-author DOI 10.1245/s10434-018-07148-z↗
  35. ASO Author Reflections: Dissecting the Risk and Impact of Venous Thromboembolism During Neoadjuvant Treatment and the Subsequent Perioperative Period for Patie… Co-author DOI 10.1245/s10434-019-07396-7↗
  36. Autophagy Inhibition in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.clcc.2017.10.013↗
  37. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. Co-author DOI 10.1186/s12885-018-4584-2↗
  38. RAGE-specific single chain Fv for PET imaging of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0192821↗
  39. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Co-author DOI 10.1038/cgt.2015.21↗
  40. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4566-4↗
  41. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreati… Co-author DOI 10.1002/jso.23606↗
  42. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-014-3842-z↗
  43. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. Co-author DOI 10.1002/jso.23392↗

Grants 3

  1. Research Recovery Grant: Brian Boone (bacterial-derived immunotherapy in pancreatic adenocarcinoma) AWARD pancan:2026-brian-boone-md-research-recovery-grant-brian-boone-bact
  2. Metabolic adaptations to crisantaspase treatment mediated by the pancreatic ductal adenocarcinoma P20GM121322↗
  3. Mechanisms of anti-tumor activity of group A Streptococcus in pancreatic adenocarcinoma R21CA267302↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Herbert J. Zeh · 22 shared papers, 2013–2026 · strength 2.27
  2. Amer H. Zureikat · 17 shared papers, 2013–2026 · strength 1.79
  3. Melissa Ellen Hogg · 12 shared papers, 2014–2026 · strength 1.44
  4. Tracy W. B. Liu · 5 shared papers, 2024–2026 · strength 1.36
  5. Timothy D. Eubank · 6 shared papers, 2021–2026 · strength 1.32
  6. Dominique Bollino · 1 shared grant, 2026 · strength 1.26
  7. Nathan Bahary · 13 shared papers, 2013–2022 · strength 1.20
  8. Michael T. Lotze · 12 shared papers, 2015–2021 · strength 1.11
  9. Emily A. Henderson · 3 shared papers, 2023–2026 · strength 1.03
  10. Aatur Dilip Singhi · 11 shared papers, 2014–2022 · strength 0.95
  11. Alessandro Paniccia · 7 shared papers, 2019–2026 · strength 0.95
  12. Hillary G. Pratt · 4 shared papers, 2021–2026 · strength 0.86
  13. Angisha Basnet · 3 shared papers, 2024–2025 · strength 0.78
  14. Slawomir Lukomski · 1 shared grant, 2023 · strength 0.77
  15. Britney R. Niemann · 3 shared papers, 2025 · strength 0.77
  16. Pranav Murthy · 6 shared papers, 2018–2021 · strength 0.72
  17. Asmita Chopra · 4 shared papers, 2021–2026 · strength 0.65
  18. Alyson M. Stevens · 2 shared papers, 2025–2026 · strength 0.50
  19. Mercy Mayowa Ojetunde · 2 shared papers, 2025–2026 · strength 0.50
  20. Pavan Rao · 2 shared papers, 2021–2025 · strength 0.49
  21. Sarah B. Hays · 2 shared papers, 2025–2026 · strength 0.42
  22. Patricio Marcelo Polanco · 2 shared papers, 2025–2026 · strength 0.42
  23. Emile Farah · 2 shared papers, 2025–2026 · strength 0.42
  24. Mark S. Talamonti · 2 shared papers, 2025–2026 · strength 0.42
  25. Caroline J. Rieser · 3 shared papers, 2019–2025 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.